Abstract: A system and method for real time ramping, up or down, of computer processing units (CPUs) in operation based on available power from a variable power generation asset is disclosed. The system is configured with a power detection unit to analyze power provided from the variable power generation asset without the need for complex and expensive custom engineering integration. The power detection unit is configured to analyze voltage along the voltage mains line from the supplied power and apply a test load comparable to the load of one or more CPUs in a manner which does not negatively impact the CPUs already in operation. The system is able to ramp up CPUs in operation when additional power is available and ramp down CPUs when power is declining to avoid cycling of the computers when power demands exceed power availability. The system enables optimized operation of CPUs within a data center and can be implemented through a power control unit or a software control unit.

Abstract: Monitoring and recycling gases from acetic acid hydrogenation reaction to maintain a constant pressure in the hydrogenation reaction system. Purging of the vapor stream comprising hydrogen may be limited or reduced. Further purging of the by-product may be from the dissolved by-product gases.

Abstract: Catalysts and processes for forming catalysts for use in hydrogenating acetic acid to form ethanol. The catalyst comprises palladium and chromium on a support.

Abstract: Monitoring and recycling gases from acetic acid hydrogenation reaction to maintain a constant pressure in the hydrogenation reaction system. Purging of the vapor stream comprising hydrogen may be limited or reduced. Further purging of the by-product may be from the dissolved by-product gases.

Abstract: Catalysts and processes for forming catalysts for use in hydrogenating acetic acid to form ethanol. The catalyst comprises palladium and chromium on a support.

Abstract: Catalysts and processes for forming copper catalysts for use in hydrogenating acetic acid to form ethanol. The catalyst may also comprise a second metal selected from the group consisting of chromium, palladium, platinum, rhodium, ruthenium, silver, tungsten, vanadium, and zinc.

Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1-34) fragment are disclosed that combine the N-terminal signaling domain (residues 1-9) and the C-terminal binding domain (residues 15-31) via a linker. Nucleic acid molecules and peptides for PTH(1-9)-(Gly)5-PTH(15-31) (PG5) and PTH(1-9)-(Gly)7-PTH(15-31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.

Abstract: The invention provides a novel PTH receptor polypeptide, r?Nt, characterized by a deletion of the extracellular amino-terminus, ligand binding domain of the receptor. Additionally disclosed are nucleic acid molecules encoding the receptor. The receptor has a minimal domain for ligand binding and is useful in screening assays designed for the identification of agonists and antagonists of PTH receptor activity.

Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.

Abstract: The present invention relates to methods of treatment of mammalian conditions characterized by decreases in bone mass with conformationally constrained parathyroid hormone (PTH) analogs and derivatives of those analogs containing PTH polypeptide derivatives containing at least one Glu or Lys substitution at position 6 and/or 10, some with installed lactam bridges between the side chains of Lys and Glu. The invention provides derivatives of PTH (1-34), PTH(1-33), PTH(1-32), PTH(1-31), PTH(1-30), PTH(1-29), PTH(1-28), PTH(1-27), PTH(1-26), PTH(1-25), PTH(1-24), PTH(1-23), PTH(1-22), PTH (1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11), PTH(1-10) and PTH(1-9) polypeptide. The invention also provides methods of preparing the PTH analogs. Further, the invention encompasses treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g.

Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1-34) fragment are disclosed that combine the N-terminal signaling domain (residues 1-9) and the C-terminal binding domain (residues 15-31) via a linker. Nucleic acid molecules and peptides for PTH(1-9)-(Gly)5-PTH(15-31) (PG5) and PTH(1-9)-(Gly)7-PTH(15-31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.

Abstract: Methods of fabricating optical elements that are encapsulated in monolithic matrices. The present invention is based, at least in one aspect, upon the concept of using multiphoton, multi-step photocuring to fabricate encapsulated optical element(s) within a body of a photopolymerizable composition. Imagewise, multi-photon polymerization techniques are used to form the optical element. The body surrounding the optical element is also photohardened by blanket irradiation and/or thermal curing to help form an encapsulating structure. In addition, the composition also incorporates one or more other, non-diffusing binder components that may be thermosetting or thermoplastic. The end result is an encapsulated structure with good hardness, durability, dimensional stability, resilience, and toughness.

Abstract: Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.

Abstract: Methods of fabricating optical elements that are encapsulated in monolithic matrices. The present invention is based, at least in one aspect, upon the concept of using multiphoton, multi-step photocuring to fabricate encapsulated optical element(s) within a body of a photopolymerizable composition. Imagewise, multi-photon polymerization techniques are used to form the optical element. The body surrounding the optical element is also photohardened by blanket irradiation and/or thermal curing to help form an encapsulating structure. In addition, the composition also incorporates one or more other, non-diffusing binder components that may be thermosetting or thermoplastic. The end result is an encapsulated structure with good hardness, durability, dimensional stability, resilience, and toughness.

Abstract: Synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28), comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula: (a) X01ValSerGluIleGlnLeuMetHisAsn (SEQ ID NO:1); LeuGlyLysHisLeuAsnSerMetX02Arg ValGluTrpLeuArgLysLysLeu (b) fragments thereof containing amino acids 1-24, 1-25, 1-26, or 1-27; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein: X01 is Ser, Ala or Gly; and X02 is Glu or Arg, provided that said peptide is not hPTH(1-26)NH2, hPTH(1-27)NH2 or hPTH(1-28)NH2.

Abstract: A belt tensioner comprises first and second pulleys, a main arm and a sub-arm. The first pulley is displacable relative to an engine, and the second pulley is displacable relative to the first pulley. The main arm is connected to the first pulley, and a first spring is connected to the main arm and resists displacement of the first pulley when the engine is started. The sub-arm is connected to the second pulley, and a second spring is connected between the main arm and the sub-arm and maintains the second pulley generally equidistant from the first pulley while the engine is running.

Abstract: Microresonators, such as a microsphere resonators and planar microresonators, are optically coupled to waveguides for input and output of light. It is important that the relative positions of the microresonator and the waveguide are maintained stable, while still maintaining high cavity Q and ease of launching and extracting the optical beams. Structures are provided on a substrate that are useful for maintaining the position of the microresonator relative to the waveguide. The structures provide for vertical or horizontal coupling between the waveguide and the microresonator.

Abstract: A method for making a plurality of waveguide resonator devices is disclosed herein. The method includes fixing a precursor resonator structure relative to a plurality of waveguides. The method also includes dividing the precursor resonator structure into a plurality of separate resonators after the precursor resonator structure has been fixed relative to the waveguides. The precursor resonator structure is divided at locations between the waveguides.